Edition:
United States

Celsion Corp (CLSN.PH)

CLSN.PH on Philadelphia Stock Exchange

1.21USD
22 Jul 2016
Change (% chg)

-- (--)
Prev Close
$1.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
213
52-wk High
$2.62
52-wk Low
$1.06

Latest Key Developments (Source: Significant Developments)

Celsion expects to report translational data from first two cohorts of ovation study in Q3
Tuesday, 24 May 2016 08:00am EDT 

Celsion Corp : Celsion Corp Says Has Completed Enrollment Of Second Cohort Of Ovation Study And Expects To Report Clinical Data From That Cohort Mid Year . Celsion Corp says also expects to report translational data from first two cohorts of ovation study early in Q3 of 2016 .Celsion announces presentation of ovation study clinical trial design at upcoming asco 2016 meeting.  Full Article

Celsion Corp Q1 loss per share $0.24
Monday, 16 May 2016 08:21am EDT 

Celsion Corp : Celsion corporation reports first quarter 2016 financial results and provides business update . Q1 loss per share $0.24 .Q1 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

Celsion receives CFDA approval to conduct OPTIMA study in China
Wednesday, 16 Dec 2015 08:00am EST 

Celsion Corp:Announced that it has received Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct the ongoing Phase III OPTIMA Study at clinical sites in China.  Full Article

Celsion Corp announces preclinical data of ovarian cancer drug
Monday, 12 Oct 2015 08:00am EDT 

Celsion Corp:Announces impressive preclinical data for its gen-1 il-12 immunotherapy in combination with avastin® and doxil® for ovarian cancer.Says phase 1/2 combination trial is expected to begin in mid-2016.Results show gen-1 when combined with avastin,doxil,showed greater than 98% reduction in tumor burden when compared to untreated control group.  Full Article

Celsion presents gen-1 immunotherapy phase 1b results in recurrent ovarian cancer
Monday, 1 Jun 2015 08:00am EDT 

Celsion Corp:Presents gen-1 immunotherapy phase 1b results in recurrent ovarian cancer at asco 2015.Says significant clinical benefit observed at highest dose of gen-1 in platinum resistant ovarian cancer.Gen-1 was well tolerated, with no dose limiting toxicities and no overlapping toxicities between gen-1 and pegylated doxorubicin.Since maximum tolerated dose was not reached, co to evaluate gen-1 in phase 1 dose escalating trial in first line neoadjuvant ovarian cancer.Plans to initiate phase 1b dose escalating trial evaluating gen-1 plus avastin and doxil in platinum-resistant ovarian cancer patients.  Full Article

Celsion Corp announces $8 mln at-the-market registered direct offering
Thursday, 28 May 2015 08:45am EDT 

Celsion Corp:Says two institutional healthcare investors to purchase an aggregate of about $8 mln of common stock in a direct offering and a concurrent private placement of warrants to purchase common stock.Enters into a definitive purchase agreement with these investors pursuant to which the Company agreed to sell an aggregate of 3,000,000 shares of its common stock at a per share price of $2.675 in a registered direct offering.To issue to the investors warrants to purchase, for each share of common stock purchased in the registered direct offering, 0.65 share of common stock for a total of 1,950,000 shares of common stock.Warrants have an exercise price of $2.60 per share and will expire five years from the date of issuance.Closing of the registered direct offering and the concurrent private placement is expected to take place on or about June 1.Net proceeds to the Company from the sale of the shares of common stock in the registered direct offering are expected to be about $7.3 mln.Intends to use the net proceeds for general corporate purposes.Maxim Group LLC is acting as sole placement agent in connection with the registered direct offering and concurrent private placement.  Full Article

Celsion Corp expands clinical development plan for GEN-1 IL-12 immunotherapy program in Ovarian Cancer
Wednesday, 29 Apr 2015 08:00am EDT 

Celsion Corp:Says an update on its clinical development plans for GEN-1, Company's DNA-based immunotherapy for the localized treatment of cancer, in ovarian cancer.GEN-1 has demonstrated promising clinical activity and tolerability in platinum-resistant and recurrent ovarian cancer patients, as well as synergistic anti-cancer effects in combination with bevacizumab (Avastin®) in preclinical models.Plans to expand its ovarian cancer development program to include a Phase 1 dose escalating trial evaluating GEN-1 in combination with Avastin and Doxil in platinum-resistant ovarian cancer patients, expected to begin in H2 of 2015.As previously reported, Celsion intends to commence Phase 1b dose escalating trial in newly diagnosed ovarian cancer patients in Q3 of this year.  Full Article

Celsion Corp announces positive interim data from Phase 2 DIGNITY Study in Breast Cancer
Wednesday, 15 Apr 2015 08:00am EDT 

Celsion Corp:Says positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in recurrent chest wall (RCW) breast cancer.The trial is designed to enroll up to 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia.The company remains on track to complete enrollment in the study in the third quarter of 2015.  Full Article

Celsion Corp announces updated overall survival data from HEAT Study of ThermoDox in Primary Liver Cancer
Monday, 23 Feb 2015 08:00am EST 

Celsion Corp:Says updated results from its retrospective analysis of company's 701-patient HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC).As of Jan. 15 latest quarterly overall survival (OS) analysis demonstrated that in large, well bounded, subgroup of patients (n=285, 41 pct of study patients), combination of ThermoDox and optimized RFA provided a 59 pct improvement in OS compared to optimized RFA alone.Says Hazard Ratio at this analysis is 0.628 (95 pct CI 0.420 - 0.939) with p-value of 0.02.Data from most recent quarterly HEAT Study post-hoc analysis continued to strongly suggest that ThermoDox may significantly improve OS compared to RFA control in patients whose lesions undergo optimized RFA treatment for 45 minutes or more.These findings apply to patients with single HCC lesions (64.4 pct of the HEAT Study population) from both size cohorts of HEAT Study (3-5 cm and 5-7 cm) and represent subgroup of 285 patients.  Full Article

Celsion Corporation and myTomorrows Partner to Introduce ThermoDox Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer
Tuesday, 20 Jan 2015 08:00am EST 

Celsion Corp:Signs a license and distribution agreement with myTomorrows.To implement an Early Access Program for ThermoDox, in all countries of the European Union (EU) territory plus Switzerland for the treatment of patients with recurrent chest wall (RCW) breast cancer.  Full Article

BRIEF-Celsion Corp says updates on OVATION study

* Celsion Corp says announces positive data from OVATION study Source text for Eikon: Further company coverage: